EGFR and chronic myelogenous leukemia, BCR-ABL1 positive: HER2 blockade (trastuzumab) in HER2-positive breast cancer, tyrosine kinase inhibitor in CRC and chronic myelogenous leukemia, and inhibitors of EGFR in EGFR-mutated lung cancer are clinically established as examples of targeted therapy [130].